Gilead Sciences Inc.
Gilead Reports Q4 and FY 2024 Results: Revenue Up, EPS Down
Summary
Gilead Sciences, Inc. announced its financial results for the quarter and year ended December 31, 2024. Total revenue increased by 6% to $7.6 billion for the fourth quarter and $28.8 billion for the full year. Product sales excluding Veklury increased by 8% to $26.8 billion for the full year, driven by growth in HIV, Oncology, and Liver Disease sales. However, full-year diluted EPS decreased to $0.38 due to IPR&D impairment charges and higher expenses. Gilead also provided guidance for full-year 2025, expecting product sales between $28.2 billion and $28.6 billion.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement